The anticancer agents @entity1487 , raltitrexed, @entity2600 and @entity901 show limited efficacy in the treatment of @entity14 and may be associated with substantial @entity137 . Therefore, the prevention and reduction of chemotherapy-induced adverse effects is of major significance, in accordance with the increasing concern for the quality of life of @entity1 with @entity5 . Therapeutic drug monitoring of @entity1487 and chronomodulation of @entity1487 and @entity901 , have been effective in reducing the incidence and gravity of adverse effects in several clinical trials. However, these concepts have not been implemented in clinical practice yet. At the present time, dose adaptation and supportive measures are the main tools for @entity137 control in the treatment of @entity14 . In this review, supportive measures for alleviation of the adverse effects of @entity1487 , raltitrexed, @entity2600 and @entity901 , respectively, are described, based on study results. The main adverse effects of these agents are myelosuppression, @entity3136 , @entity294 , @entity27081 , @entity390 and emesis, @entity2359 , @entity8566 and other cutaneous adverse effects, @entity2194 , @entity1370 , small bowel @entity137 , @entity1395 , elevated liver transaminase levels and @entity1665 . The incidence and gravity of these adverse effects are more or less related to the agent and administration schedule involved. The supportive measures and recommendations include the use of specific drugs, alterations of administration schedule and several nonpharmacological methods. In addition, guidelines for dosage adjustments when @entity137 occurs are presented. For optimal management of adverse effects, @entity1 should be considered individually, while @entity1 , nurses and physicians should cooperate to identify and treat adverse effects in an early stage of their development.

Management of chemotherapy-induced adverse effects in the treatment of XXXX .

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular toxicity'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['oral mucositis'] @entity27081 :: ('MESH:C535672', 'Disease') :: ['acute cholinergic syndrome'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity'] @entity1395 :: ('MESH:D001247', 'Disease') :: ['asthenia'] @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-foot syndrome'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxicity'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
